Timeline

Voting rights breakdown

Notice details

Beneficial owner

Idorsia Ltd

Granting of the warrants as an arrangement fee as disclosed in the disclosure notification dated March 3, 2025. As disclosed in the disclosure notification dated March 3, 2025, Idorsia Ltd (the "Company") and Idorsia Pharmaceuticals Ltd ("IPL") have entered into a lock-up agreement with certain bondholders dated 25 February 2025 (the "Lock-Up Agreement") and a backstop letter agree-ment with certain bondholders dated 25 February 2025 (the "Backstop Letter", collectively the "Agreements"), pursuant to which the Company and/or IPL have agreed to the following rights and obligations: (i) to deliver 32,540,000 registered shares, (ii) to grant/issue 25,540,000 warrants (the "Warrants") and (iii) to repurchase part of its convertible bonds 2025 (ISIN CH0426820350; 0.75 IDORSIA CV 18-25) issued by the Company (the "CB25") and its convertible bonds 2028 (ISIN CH1128004079; 2.125 IDORSIA CV 21-28) issued by the Company (the "CB28"). As disclosed in the disclosure notification dated March 10, 2025, the Company increased its share capital in order to be able to deliver the registered shares in due time. As disclosed on March 14, 2025, the registered shares as backstop fee were delivered. As disclosed on March 19, 2025, the registered shares as an advisor fee were delivered. As disclosed on May 27, 2025, the warrants as a backstop fee were delivered. After granting of the warrants as an arrangement fee, and as of August 22, 2025, the Company and/or IPL have the remaining following rights and obligations with regard to the above and, with regard to (iii) below, under the repurchase offer launched on June 25, 2025: (i) to deliver registered shares to certain bondholders as per different conditions and milestone events as defined in the Agreements; the share delivery obligations are set as follows: a) delivery of registered shares as an arrangement fee: 10,500,000 registered shares; and b) delivery of registered shares as an exchange fee: 8,040,000 registered shares. (ii) to grant/issue warrants as an exchange fee for up to 8,040,000 registered shares to certain bondholders as per different conditions and milestone events as defined in the Agreements and that (i) will mature on June 2, 2027, and (ii) have an exercise price of CHF 1.50 per warrant. (iii) to repurchase the following with regard to the CB25 and the CB28: a) 29,682,000 voting rights with regard to CB25; and b) 17,317,691 voting rights with regard to CB28.